preparing 293ft cells transfected with pcmv5-nanoluc-craf and pcmv5-14-3-3&#950;-halo for bret emission assay

CRAF-14-3-3 Analyse de l’interaction dans des cellules vivantes à l’aide d’une approche basée sur BRET

RAF kinases (ARAF, BRAF, and CRAF) are the direct effectors of RAS GTPases and the initiating members of the pro-proliferative/pro-survival RAF-MEK-ERK kinase cascade. Recent studies have shown that CRAF expression plays a key role in the tumorigenesis of several KRAS-driven cancers, including non-small cell lung cancer and pancreatic ductal adenocarcinoma1,2,3,4,5. Moreover, germline CRAF mutations cause a particularly severe form of the RASopathy, Noonan syndrome6,7. Understanding CRAF regulation is critical for developing successful therapeutic approaches that target its function in cells.
All RAF kinases can be divided into two functional domains, a C-terminal catalytic (CAT) domain and an N-terminal regulatory (REG) domain, that controls its activity (Figure 1A)8. The REG domain encompasses the RAS binding domain (RBD), the cysteine-rich domain (CRD), and a serine/threonine-rich region (S/T-rich). Notably, the S/T-rich region contains the N&#39; site, which binds to 14-3-3 in a phosphorylation-dependent manner (S259 in CRAF; Figure 1A)8. The CAT domain encompasses the kinase domain, along with a second high-affinity 14-3-3 docking site, referred to as the C&#39; site (S621 in CRAF; Figure 1A)8. The differential binding of dimeric 14-3-3 proteins to the N&#39; and C&#39; sites, along with the CRD, plays critical roles in both RAF activation and inhibition9,10,11,12,13. Under normal signaling conditions, RAF activation is initiated by its recruitment to the plasma membrane by RAS, allowing it to form active dimers, of which the BRAF-CRAF heterodimer is the predominant active form14,15. Biochemical assays with BRAF and CRAF, along with cryogenic electron microscopy (Cryo-EM) structures of dimeric BRAF, indicate that a 14-3-3 dimer stabilizes active RAF dimers by binding simultaneously to the C&#39; site of both RAF protomers (Figure 1B)9,13,16,17. Conversely, studies have shown that under quiescent conditions, RAF adopts a cytosolic, autoinhibited confirmation, where the REG domain binds to the CAT domain and inhibits its activity12,18,19,20. This closed state is stabilized by a 14-3-3 dimer bound to the CRD and N&#39; site in the REG domain and to the C&#39; site in the CAT domain (Figure 1B)10,13,21. In BRAF, this model is supported by recent Cryo-EM structures of autoinhibited BRAF monomers and by our previous biochemical studies10,12,13,21,22. However, while 14-3-3 is shown to play an inhibitory role in CRAF regulation23, a BRAF-like autoinhibited state may play a lesser role in CRAF regulation12; therefore further studies are required to clarify the mechanisms by which 14-3-3 proteins regulate CRAF activity. The 14-3-3-mediated regulation of RAF kinases requires a plethora of RAF phosphorylation and de-phosphorylation events, the binding to various regulatory proteins, and interactions with the plasma membrane8. Therefore, it is critical that 14-3-3-RAF interactions are measured under physiologically relevant conditions and in the presence of an intact lipid bilayer.
To address this issue, NanoBRET (from here on referred to as N-BRET; see Table of Materials for kit details) technology was utilized to develop a proximity-based assay for measuring the interactions of CRAF with 14-3-3 proteins in live cells (Figure 1C). This BRET-based system measures the interactions of two proteins of interest (POI), where one protein is tagged with a nanoluciferase (Nano) donor and the other with a Halo tag, for labeling with the Halo618 energy acceptor ligand22,24. Interaction of the proteins of interest results in donor to acceptor energy transfer, which in turn generates the BRET signal (Figure 1C). The extremely bright Nano donor protein (emission (em) 460 nm) and the Halo618 ligand (em 618 nm) provide greater spectral separation and sensitivity over conventional BRET, making it an ideal platform for studying weaker interactions and detecting subtle changes in binding24. Indeed, we previously developed a N-BRET-based assay for measuring the autoinhibitory interactions of the RAF REG and CAT domains, which was essential for the characterization of a panel of RASopathy mutations in the BRAF CRD and demonstrated the critical importance of this domain for maintaining autoinhibition and preventing constitutive BRAF activation12.
The assay described here measures the interactions of CRAF, fused to an N-terminal Nano tag (Nano-CRAF), and the zeta isoform of 14-3-3 fused to C-terminal Halo tag (14-3-3&#950;-Halo; Figure 1C). We show that the interactions of Nano-CRAF with 14-3-3&#950;-Halo generates a robust BRET signal, which can in turn be disrupted by mutations which prevent 14-3-3 binding to the N&#39; site (S259A) and/or the C&#39; site (S621A). The following protocol provides detailed steps for performing, optimizing, and troubleshooting this assay.

Pleins feux sur l’auteur : Intégration des tests basés sur BRET et de l’analyse des mutations rares pour déchiffrer la régulation de la kinase RAF dans les cellules vivantes

Dosage basé sur le transfert d’énergie par résonance de bioluminescence (BRET) pour mesurer les interactions de CRAF avec les protéines 14-3-3 dans les cellules vivantes

The primary focus of our research is to uncover new vulnerabilities in the Ras-MAPK kinase pathway through the study of rare disease associated mutations within. We recently developed another BRET-based assay for measuring the auto inhibitory activities of RAF kinases in live cells. Importantly, this assay was essential for characterizing a group of rare germline mutations in the BRAF cysteine rich domain, which demonstrated the critical importance of this domain for maintaining BRAF auto inhibition and for preventing constitutive BRAF biological activity.This assay measures the interactions of 1433 proteins with the RAF kinase CRAF, and these interactions play essential roles in mediating RAF function in both development and disease. In addition, this assay combined with previously established assays for measuring RAF auto inhibition and the RAF-RAF interaction form the basis of a toolkit for dissecting the regulatory mechanisms of RAF kinases in live cells.

Préparation de cellules de 293FT transfectées avec pCMV5-NanoLuc-CRAF et pCMV5-14-3-3ζ-Halo pour le dosage de l’émission BRET

Research

JoVE Journal

Biochemistry

Preparing 293FT Cells Transfected with pCMV5-NanoLuc-CRAF and pCMV5-14-3-3&#950;-Halo for BRET Emission Assay

CRAF-14-3-3 Interaction Analysis in Live Cells Using a BRET-Based Approach

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

CRAF is a primary effector of RAS GTPases and plays a critical role in the tumorigenesis of several KRAS-driven cancers. In addition, CRAF is a hotspot ...

Recherche

Biochimie

Transfection of 293FT Cells with pCMV5-NanoLuc-CRAF and pCMV5-14-3-3&#950;-Halo Expression Constructs

Transfection de cellules 293FT avec les constructions d’expression pCMV5-NanoLuc-CRAF et pCMV5-14-3-3ζ-Halo